Skip to content

Impact of FDG-PET/CT on Management of Patients with Native Valve Infective Endocarditis

Impact of FDG-PET/CT on Management of Patients with Native Valve Infective Endocarditis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04792281
Acronym
PET-NAVIE
Enrollment
97
Registered
2021-03-10
Start date
2021-08-31
Completion date
2025-12-31
Last updated
2024-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infective Endocarditis, Native Valve Endocarditis

Keywords

PET/CT, FDG, Duke Criteria

Brief summary

The proposed study is a multicentric prospective observational cohort study of patients with suspected NVE. The study population includes those with Possible IE according to the modified Duke criteria and investigated at one of the 6 participating sites which include 2 cardiac centers, the MHI and the IUCPQ, as well as 4 tertiary care centers, the Jewish General Hospital , the McGill University Health Centre and the CHUS.

Interventions

None listed

Sponsors

Montreal Heart Institute
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years of age or older, capable to provide informed consent; * Referred for a FDG-PET/CT study * Classified as having Possible IE prior to FDG-PET/CT imaging; * Patients must be able to tolerate the physical/logistical requirements of a PET/CT scan.

Exclusion criteria

* Subjects with prosthetic cardiac valve and/or CIED; * Pregnant or breastfeeding female; * Body mass index \> 45 kg/m2.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of patients with Possible IE that will be appropriately reclassified3 monthsProportion of patients with Possible IE that will be appropriately reclassified as Definite IE by the addition of FDG-PET to the Duke criteria.

Secondary

MeasureTime frame
Differences in maximal standardized uptake value (SUVmax) between infected and non-infected valves3 months
Proportion of patients with final diagnosis of IE with septic emboli detected on whole body FDGPET3 months
Differences in the rate of sub-optimal suppression protocol between males and females3 months
Proportion of patients with incidental cancer identified on FDG-PET3 months
Sensitivity, specificity, and accuracy of FDG-PET for the detection of NVE3 months
Sensitivity, specificity, and accuracy of the Duke criteria with FDG-PET for detection of NVESensitivity, specificity, and accuracy of the Duke criteria with FDG-PET for detection of NVE3 months
Sensitivity, specificity, and accuracy of the Duke criteria with FDG-PET but excluding TEE for the detection of NVE3 months
Differences target-to-background ratio (TBR) between infected and non-infected valves3 months
Proportion of patients in whom a TEE was not necessary to diagnose NVE through the addition of FDG-PET3 months

Other

MeasureTime frameDescription
Differences in sensitivity, specificity, and accuracy of FDG-PET with and without respiratory and ECG-gated acquisitions3 months
Difference in the area under the curve (c-statistic) of the Duke criteria with TEE but excluding FDG-PET, with TEE and FDG-PET, and with FDG-PET but excluding TEE3 months
Correlation between the diagnostic accuracy and available demographic, technical, and clinical factors3 monthsCorrelation between the diagnostic accuracy (false-negative/false-positive studies versus truenegative/true-positive) and the available demographic and clinical factors (age, sex, duration of antibiotherapy, blood glucose, CRP, history of renal failure, history of malignancy, history of diabetes, chronic liver disease, time since onset of symptoms, and quality of myocardial suppression) as well as camera system (analog vs digital)

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026